SAN DIEGO, Aug. 25, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that Steve Martin, Senior Vice President and Chief Financial Officer, will present a company overview at the 2011 Southern California Investor Conference on Monday, August 29, 2011 at 2:30pm PT at The Island Hotel in Newport Beach, CA.
Mr. Martin's presentation will be webcast live, accessible to the public online at http://events.powerstream.net/002/00271/20110829_SCIC_T2/">http://events.powerstream.net/002/00271/20110829_SCIC_T2/ or via Apricus Bio's web site at http://www.apricusbio.com.
The corporate presentation will include a discussion of the Company's recent announcements regarding receipt of FDA approval to market its first two anti-fungal, over-the-counter ("OTC") drugs, Tolnaftate-D™ and Hydrocortisone-D™, each containing the NexACT® technology. Tolnaftate, an already approved anti-fungal agent, which can be sold as a cream, powder, spray or liquid aerosol, is currently used to treat jock itch, athlete's foot and ringworm and is sold under several third party brand names, most notably Tinactin® (Merck) and Lamisil AF® (Novartis), among others. Hydrocortisone is also an already approved anti-itch agent, which can be sold as a cream. It is currently used to treat itching associated with minor skin irritations, inflammation and rashes due to eczema, insect bites, poison ivy, poison oak and psoriasis, among others. It is sold under several third party brand names, most notably Corizone® (Chattern/Sanofi Avewntis) and Cortaid® (Johnson & Johnson).
With the approval of Tolnaftate-D™ and Hydrocortisone-D™, DDAIP, the mainstay of Apricus Bio's NexACT® technology, is now listed as an excipient in an approved drug and is part of the U.S. monograph (the underlying FDA regulatory document). As such, DDAIP can be combined with active ingredients listed in the monograph to develop a greater number of OTC products, which can be sold in the U.S.
Mr. Martin will also provide a review of Apricus Bio's partnership plans for Canada and Europe for Vitaros®, which has been approved for marketing in Canada as a topical treatment for erectile dysfunction. The Company is currently in active negotiations for both individual and bundled partnership agreements relating to Canada and Europe, and is proceeding with manufacturing, scale-up and commercial batches of the drug for Canada, where it is expected to be available later this year.
Additionally, an overview of the status of Apricus Bio's later stage pipeline will also be provided, including: Femprox® for female sexual arousal disorder, MycoVa™ for onychomycosis (toe nail fungus, excluding Tinea Pedis), PrevOnco® for human hepatocellular carcinoma (liver cancer) and RayVa™ for Raynaud's Syndrome.
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego-based, revenue-generating, biopharmaceutical company, has leveraged the flexibility of its clinically-validated NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes.
Revenues and growth are driven from out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies worldwide. In addition, the Company is seeking to monetize its existing product pipeline, including its first product, Vitaros®, approved in Canada for the treatment of erectile dysfunction, which is currently expected to be available on the Canadian market in 2011, as well as compounds in development from pre-clinical through Phase III, currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals among others. The Company is also developing its over-the counter ("OTC") products division by seeking clearance for a number of drugs that contain active ingredients listed in the OTC drug monograph, combined with Apricus Bio's NexACT® technology.
For further information on Apricus Bio, visit http://www.apricusbio.com and for information on its subsidiary please visit www.nexmedusa.com. You can also receive information at http://twitter.com/apricusbio and http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to receive issued patents on its NexACT® technology and products, develop such patented technology into product candidates, have its products and product candidates such as Vitaros® approved by relevant regulatory authorities, to successfully commercialize such products including over-the-counter products ("OTC") and product candidates and to achieve its other development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.